Virtus Health (ASX:VRT) share price shrugs off latest acquisition hurdle

The Virtus share price was unfazed by today's seemingly unfortunate news.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Virtus Health Ltd (ASX: VRT) share price spent most of today in the green despite its planned acquisition being faced with a new challenge.

The company is waiting to complete its acquisition of Adora Fertility and 3 day hospitals, together known as the Adora Businesses. Currently, Healius Ltd (ASX: HLS) owns the Adora Businesses.

However, today Virtus announced the Australian Competition and Consumer Commission (ACCC) is planning to stop the acquisition from being finalised.

Despite the apparent bad news, Virtus performed quite well on the ASX today.

As of Wednesday's close, the Virtus share price is $5.47, 0.37% higher than Tuesday's closing price.

For context, the S&P/ASX 200 Index (ASX: XJO) fell 0.07% today.

Let's take a closer look at the new hurdle facing the healthcare company specialising in fertility treatments and day hospital services.

a man in a suit holds up a hand and a stop sign at a roadblock positioned over a bitumen road .

Image source: Getty Images

Virtus unfazed by ACCC roadblock

The Virtus share price gained today despite announcing seemingly unfortunate news.

The company has had its plans to acquire Adora Fertility and 3 day hospitals halted by the ACCC.

According to Virtus, the watchdog intends to seek an interim order from the Federal Court to prevent the acquisition's completion despite the ACCC's public review not being finalised.

However, Virtus is still planning to complete the acquisition. It said it will defend any proceedings.

The company also noted it has kept the ACCC in the loop throughout the acquisition process.

Virtus stated it has "constructively engaged" with the watchdog since it announced it would conduct a public review process of the acquisition

Virtus first announced its plans to acquire Adora Fertility and the 3 day hospitals back in August. It agreed to pay $45 million for the businesses. The funds were to come from a now-completed $35 million capital raise and existing cash reserves.

Virtus share price snapshot

Right now, the Virtus share price is around 3% higher than it was at the start of 2021. It is also 23% higher than it was this time last year.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Virtus Health Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Two happy pharmacists standing together in a pharmacy.
Healthcare Shares

Why Clarity Pharmaceuticals shares just fell 5% on today's announcement

Investors are balancing Clarity's long-term potential against near-term uncertainty.

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Healthcare Shares

Still down 40%, are Pro Medicus shares primed to break out?

Two major US contract wins in as many weeks could mark a turning point in sentiment.

Read more »

Happy healthcare workers in a lab.
Healthcare Shares

Telix share price leaping higher today on $3 billion US news

Investors are snapping up Telix shares on Monday following big US news.

Read more »

Four smiling young medics with arms crossed stand outside a hospital.
Healthcare Shares

Pro Medicus locks in 5-year, $37m Northwestern Medicine contract renewal

Pro Medicus has renewed its major contract with Northwestern Medicine, locking in higher fees and strengthened client ties for the…

Read more »

Rising healthcare ASX share price represented by doctor giving thumbs up
Healthcare Shares

Telix Pharmaceuticals announces US$40m Regeneron radiopharma deal

Telix Pharmaceuticals has announced a US$40m strategic collaboration with Regeneron for innovative radiopharmaceutical cancer therapies.

Read more »

Two health workers taking a break.
Healthcare Shares

It could be time to buy-low on this ASX small-cap stock according to brokers

This ASX healthcare stock keeps attracting positive ratings, with one broker now tipping a 268% rise.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

Broker sees 26% upside in ASX healthcare share behind Chemist Warehouse

Morgans has just upgraded its rating on this ASX healthcare stock due to ongoing share price weakness.

Read more »

Woman using a pen on a digital stock market chart in an office.
Healthcare Shares

Why this ASX healthcare stock is surging while the market sinks on Middle East fears

Avita shares surge as a US government contract boosts sentiment again

Read more »